New ASTRO white paper recommends best practices to improve safety and effectiveness of IGRT

April 18, 2013, American Society for Radiation Oncology

The American Society for Radiation Oncology (ASTRO) has issued a new white paper, "Assuring Safety and Quality in Image Guided Delivery of Radiation Therapy," that recommends best practices to improve the safety and effectiveness of image guided radiation therapy (IGRT), according to the manuscript published as an article in press online in Practical Radiation Oncology (PRO), the official clinical practice journal of ASTRO. The executive summary and supplemental material are available online immediately as open-access articles (http://www.practicalradonc.org) and will be published in a 2013 print edition of PRO.

Commissioned by ASTRO's Board of Directors as part of ASTRO's Target Safely campaign, the recommends a set of 10 fundamental elements of IGRT safety in clinical programs and provides an additional list of recommended activities for the broader community to consider. IGRT is the use of dedicated devices for fraction-by-fraction imaging and guidance of radiation treatment delivery that localizes the target and normal structures to ensure precise and accurate placement of the radiation. IGRT-enabled accuracy and precision allows for highly conformal dose distributions, higher dose prescriptions and shorter fractionation schedules for patients. This requires a strong link between IGRT practices and planning target volume (PTV) design of a patient's , which is central to high quality, safe .

The manuscript recommends the four major categories for consideration in assuring safe, high-quality radiation therapy using IGRT technologies as: 1) commissioning and continuing quality assurance (QA) of the systems; 2) protocols for and interpretation; 3) the link between image guidance practices and PTV margin; and 4) education, training and human resources. The 10 foundational elements for safe and effective IGRT practices prescribed by the study are: 1) establish a multi-professional team responsible for IGRT activities; 2) establish and monitor a program of daily, monthly and annual QA for all new or existing IGRT sub-systems; 3) provide device- and process-specific training for all staff operating IGRT systems or responsible for IGRT delivery; 4) perform end-to-end testing for all new IGRT procedures and document performance prior to clinical release; 5) establish process-specific documentation and procedures for IGRT; 6) clearly identify who is responsible for approval of IGRT correction decisions and the process whereby the decision is made and documented; 7) establish and document site-specific planning procedures, specifically the procedure for defining PTV margins, and link these planning procedures to IGRT procedures; 8) multi-professional peer review of PTV volumes, and peer-review of gross tumor volume (GTV) / clinical target volume(CTV) by radiation oncologists; 9) verify proper creation and transfer of IGRT reference data (PTV, organs at risk (OARs), digitally reconstructed radiographs (DRRs), etc.) to IGRT system; and 10) establish a reporting mechanism for IGRT-related variances in the radiation treatment process.

"As technologies advance and we are able to provide patients with highly individualized , this white paper provides us with a thorough framework for delivering safe and effective IGRT," said David A. Jaffray, PhD, of the Radiation Medicine Program at the Princess Margaret Cancer Centre in Toronto. "In addition, it emphasizes transparency between professions and increases the awareness of all parties regarding their responsibility in achieving and maintaining safe IGRT practice."

The full text document (Supplemental Material) was approved by the ASTRO Board of Directors on June 23, 2012, and has been endorsed by the American Association of Physicists in Medicine (AAPM), American Association of Medical Dosimetrists (AAMD) and the American Society of Radiologic Technologists (ASRT). It has also been reviewed and accepted by the American College of Radiology's (ACR) Commission on Radiation Oncology. This white paper is related to other published reports in the ASTRO white paper series on patient safety, including those about the peer review process, intensity modulated radiation therapy (IMRT) and stereotactic body therapy (SBRT).

Explore further: New ASTRO white paper recommends peer review to increase quality assurance and safety

Related Stories

New ASTRO white paper recommends peer review to increase quality assurance and safety

March 21, 2013
The American Society for Radiation Oncology (ASTRO) has issued a new white paper, "Enhancing the role of case-oriented peer review to improve quality and safety in radiation oncology: Executive Summary," that recommends increased ...

ASTRO publishes white paper on IMRT safety

July 14, 2011
As part of the Target Safely initiative, the American Society for Radiation Oncology (ASTRO) has developed a white paper, the first of a series of such papers, on the safe use of integrating intensity modulated radiation ...

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers identify new treatment target for melanoma

January 16, 2018
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a new therapeutic target for the treatment of melanoma. For decades, research has associated female sex and a history of previous ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.